Galimedix is led by pharma industry veterans - the key members of the proven neuropharmaceutical team who developed and commercialized the blockbuster Alzheimer´s drug Namenda (Memantine). These experts, who led the development of GAL-101 and GAL-201 for 7 years at Merz Pharma, are now leading those efforts at Galimedix, to become an innovator of therapies in neurodegenerative diseases.


Alexander Gebauer, M.D., Ph.D.

Alexander Gebauer, M.D., Ph.D.

Co-founder, Executive Chairman

Dr. Gebauer has more than 25 years industry experience in research and development, which led to numerous approvals worldwide in several therapeutic areas. He also holds the positions of managing director and CDO of Omeicos Therapeutics, a Berlin-based biotech company. Before that, he served in several R&D roles, including managing director, president of Global R&D, chief scientific officer and other positions at several international pharmaceutical companies including Sun Pharmaceuticals, Ranbaxy Laboratories, Ltd., Merz Pharmaceuticals, Hoechst AG, Aventis and Sanofi. Dr. Gebauer studied medicine at Johannes Gutenberg University, Mainz, Germany, where he completed his thesis in pharmacology. During his time at Merz, he served as senior vice president, head of Global Research & Development and was directly involved in the development programs of GAL-101 and GAL-201.

Andrew Pearlman, Ph.D.

Andrew Pearlman, Ph.D.

Founder, President

Dr. Andrew Pearlman has more than 35 years’ experience founding and managing US/Israel biotechnology and medical device companies. A biophysicist, Dr. Pearlman has invented, licensed, developed and managed medical devices and biotechnologies from business and product concept through technology development, IP, prototyping, clinical trials, regulatory approval, manufacturing, and product sales. Dr. Pearlman has raised more than $120mm for new biomedical ventures he founded in Israel, including Medgenics, a gene therapy company he took from laboratory research stage through Phase 2 clinical trials and through IPOs on both the London Stock Exchange and the NYSE, building it to over $350 million in market cap. In less than one year, Dr. Pearlman founded Galimedix, built a world class team, and successfully completed a seed round of financing. Dr. Pearlman holds a Ph.D. in Biophysics from the University of California at Berkley (doctoral thesis under Nobel Laureates - Professors Melvin Calvin and Donald Glaser).

Hermann Russ, M.D. Ph.D.

Hermann Russ, M.D. Ph.D.

Co-Founder, Chief Scientific Officer, Board Member

Hermann Russ is a board-certified clinical neurologist, a board-certified experimental pharmacologist and a pharmacist. He is a co-founder of Galimedix. Dr. Russ is the inventor of the use of former Alzheimer-targeting molecule GAL-101 (MRZ-99030) in the treatment of degenerative diseases in the retina including glaucoma and dry macular degeneration. He is also co-inventor of the so-called "trigger effect" of GAL-101 and GAL 201, which is a unique reverse prion-like self-propagation mechanism of action important for the clinical treatment regimen. Dr. Russ championed these assets when they were being developed by Merz beginning in 2007.

He holds a Ph.D. in neuro- and bio-chemistry from the University of Wurzburg, Germany. During his academic career (until 1999) at the universities of Wurzburg, Regensburg and Giessen he had different positions and functions including consultant of clinical neurology and professor of pharmacology. His scientific focus is on neurodegenerative diseases, including Alzheimer's, Parkinson`s, and degenerative retina diseases. He is (co)inventor of around 25 patents and (co)authors of around 50 peer-reviewed scientific publications.

Dr. Russ has 20 years of Pharma industry experience. Prior to joining Galimedix he was vice president of Neuroscience Project Leadership in Specialty R&D of Teva Pharmaceuticals International GmbH (TPIG) Switzerland. His responsibilities included the strategic leadership and management of "project champions" of all global cross-functional drug development programs in the area CNS and pain throughout all phases. He also served on the Swiss Board of TPIG as Managing Officer. Prior to that he worked for 8 years at Merz Pharma as Head of Global R&D CNS leading a R&D organization in the indication areas neurology and psychiatry, spanning from early discovery to clinical development and regulatory submission. That included management of five R&D departments. From 1999 to 2007 Dr. Russ was with Merck KGaA as Head of the Medical Center of Excellence CNS (last position).

Phyllis K. Bellin, M.B.A.

Phyllis K. Bellin, M.B.A.

Board Member, Chief Financial Officer

Ms. Bellin has more than 30 years' experience in founding and leading technology-based companies. Before joining Galimedix, she served as Vice President Finance & Administration, Corporate Secretary and Treasurer at Medgenics, Inc., leading IPOs on the London AIM and the NYSE. Previously, she was an officer at Citibank in Corporate Lending and Strategic Planning. Since moving to Israel in 1980, Ms. Bellin managed finance and administration for a number of early stage high-tech ventures in automotive safety, and health care. She was also Founder and Vice President of Gintec Active Safety Limited and responsible for finance and administration of its subsidiaries including RoadEye Limited. She served on the Board of Directors of the Misgav Economic Corporation and private companies in Israel and the Netherlands. Ms. Bellin earned her MBA in Finance and Accounting from Columbia University, an MAT from the University of Chicago and a BA from Clark University.

Yaniv Barkana, M.D.

Yaniv Barkana, M.D.

Chief Medical Officer

Dr. Barkana is a Past-President of the Israel Glaucoma Society and Senior Ophthalmologist, Surgeon and head of Tele-glaucoma service at the Baruch Padeh-Poriya Medical Center Department of Ophthalmology. Until recently he has been in the glaucoma service of the Assaf Harofe Medical Center, and a Senior Clinical Lecturer at the Tel Aviv University Faculty of Medicine. He received his M.D. from the Hebrew University in Jerusalem, completed his residency in Ophthalmology at the Assaf Harofe Medical Center and his clinical fellowship in glaucoma at the New York Eye and Ear Infirmary.

Chris Parsons. Ph.D., P.D.

In memory of our esteemed co-founder Dr. Christopher Parsons. He was a scientific pioneer with deep knowledge, vision and creativity. His memory is an inspiration.